Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil

Clinical and Experimental Immunology

Volumn 129, Issue 2, 2002, Pages 214-223

  Maksimovic Ivanic, D ^a   Trajkovic, V ^b   Miljkovic, D J ^a   Mostarica Stojkovic, M ^b   Stosic Grujicic, S ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adhesion molecules; Autoimmune diabetes; Cytokines; Mycophenolate mofetil; Streptozotocin

Indexed keywords

GAMMA INTERFERON; GUANOSINE; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 12; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; STREPTOZOCIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BODY WEIGHT; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; GENETIC SUSCEPTIBILITY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; AUTOIMMUNITY; CELL ADHESION; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GUANOSINE; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; INFLAMMATION MEDIATORS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; MICE, INBRED CBA; MYCOPHENOLIC ACID; NITRIC OXIDE; RATS; STREPTOZOCIN;

EID: 0036381752     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.02001.x     Document Type: Article

References (44)

1. Kolb-Bachofen V, Epstein S, Kiesel U et al. Low dose streptozotocin induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 1988; 37:21-7.
2. Huang X, Yuan J, Goddard A et al. Interferon expression in the pancreas of patients with type I diabetes. Diabetes 1995; 44:658-64.
3. Lukic ML, Stosic-Grujicic S, Shahin A. Effector mechanisms in low dose streptozotocin induced diabetes. Dev Immunol 1998; 6:119-28.
4. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396-402.
5. Lohmann T, List C, Lamesch P et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108:347-52.
6. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997; 16:242-57.
7. Sai P, Maugendre D, Loreal O et al. Effects of cyclosporin on autoimmune diabetes induced in mice by streptozotocin. Diabetes Metabolisme 1988; 14:455-62.
8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47:85-118.
9. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8:710-20.
10. Hager PW, Collart FR, Huberman E et al. Recombinant human inosine monophosphate dehydrogenase type I and II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995; 49:1323-9.
11. Laurent AF, Dumont S, Poindron P et al. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996; 24:59-67.
12. Blaheta RA, Leckel K, Wittig B et al. Mycophenolate mofetil impairs transendothelial migration of allogenic CD4 and CD8 T-cells. Transplant Proc 1999; 31:1250-2.
13. Hao L, Chan S-M, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 1993; 696:328-32.
14. Like AA, Rosini AA. Streptozotocin-induced pancreatic insulitis. a new model of diabetes mellitus. Science 1976; 193:415-7.
15. Herold KC, Vezys V, Sun Q et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996; 156:3521-7.
16. Stosic-Grujicic S, Maksimovic D, Badovinac V et al. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun 2001; 16:47-58.
17. Stosic-Grujicic S, Dimitrijevic M, Bartlett R. Leflunomide protect mice from multiple low dose of streptozotocin (MLD-SZ)-induced insulitis and diabetes. Clin Exp Immunol 1999; 117:44-50.
18. Draskovic-Pavlovic B, Van Der Laan LJW, Pejnovic N et al. Differential effects of anti-rat CD11b monoclonal antibodies on granulocyte adhesiveness. Immunology 1999; 96:83-9.
19. Pechold K, Patterson NB, Craighead N et al. Inflammatory cytokines IFN-γ plus TNF-α induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol 1997; 158:4921-9.
20. Hibbs JB, Taintor Z, Vavrin E et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1989; 157:87-94.
21. Lukic ML, Al-Sharif R, Mostarica M et al. Immunological basis of the strain differences in susceptibility to low-dose streptozotocin-induced diabetes in rats. In: Imhof BA Berrih-Aknin S Ezine S., eds Lymphatic tissues and in vivo immune responses. New York: Marcel Dekker, 1991:643-7.
22. Lukic ML, Stosic-Grujicic S, Ostojic N et al. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochem Biophys Res Commun 1991; 178:913-20.
23. Squifflet JP, Backman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72:63-9.
24. Santamaria P. Effector lymphocytes in autoimmunity. Curr Opin Immunol 2001; 13:663-9.
25. Oon BB, Muggleston D, Warley A. A diet enriched in essential fatty acids protects against the loss of lymphocytes which occurs in rats suffering from streptozotocin-induced diabetes. Exp Physiol 1992; 77:185-90.
26. Corna D, Morigi M, Facchinetti D et al. Mycophenolate mofetil limits renal damage and prolong life in murine lupus autoimmune disease. Kidney Int 1997; 51:1583-9.
27. Allison AC, Kowalski WJ, Muller CJ et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25:67-70.
28. Tran GT, Carter N, Hodgkinson SJ. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int Immunopharmacol 2001; 1:1709-23.
29. Elliott JI, Dewchand H, Altmann DM. Streptozotocin-induced diabetes in mice lacking αβ T cells. Clin Exp Immunol 1997; 109:116-20.
30. Kiesel U, Kolb H. Suppressive effect of antibodies to immune response gene product on the development of low-dose streptozotocin-induced diabetes. Diabetes 1983; 32:869-71.
31. Farr AG, Mannschreck JW, Anderson SK. Expression of class II MHC antigens in murine pancreas after streptozotocin-induced insulitis. Diabetes 1988; 37:1373-9.
32. Stosic-Grujicic S, Mijatovic S, Ejdus L et al. Enhancement of Th2-type activity downregulated diabetes induction. Transplant Proc 1996; 28:3259.
33. Herold KC, Montag AG, Fitch FW. Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes 1987; 36:796-801.
34. Herold KC, Bluestone JA, Montag AG et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992; 41:385-91.
35. O'Brien BA, Harmon BV, Cameron DP et al. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 1996; 178:176-81.
36. Gately MK, Renzetti LM, Magram J et al. The interleukin-12/interleukin-12-receptor system. Role in normal and pathologic immune responses. Annu Rev Immun 1998; 16:495-521.
37. Rothe H, Burkart V, Faust A et al. Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 1996; 39:119-22.
38. Zipris D, Greiner DL, Malkani S et al. Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 1996; 156:1315-21.
39. Li X, Kaminski NE, Fischer LJ. Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol 2001; 1:699-712.
40. Xu D, Trajkovic V, Hunter D et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000; 30:3147-56.
41. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their role in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55:1139-49.
42. Senda M, DeLustro B, Eugui E et al. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine- induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995; 60:1143-8.
43. Durez P, Appelboom T, Pira C et al. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-α and upregulation of IL-10 release. Int J Immunopharmac 1999; 21:581-7.
44. Vallee S, Fouchier F, Braguer D et al. Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). Eur J Pharmacol 2000; 404:49-62.